berberine has been researched along with osteoprotegerin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, BY; Hasegawa, S; Iwahashi, A; Jeon, WB; Lee, JW; Nagai, K; Woo, JT; Yonezawa, T | 1 |
| Dai, Z; Guo, MF; He, XF; Li, H; Sui, FG; Tian, GF; Zhang, CH; Zhang, L; Zhang, LF; Zhao, CR | 1 |
2 other study(ies) available for berberine and osteoprotegerin
| Article | Year |
|---|---|
Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
Topics: Animals; Berberine; Bone Density Conservation Agents; Bone Marrow Cells; Calcitriol; Cell Differentiation; Cell Survival; Cells, Cultured; Coculture Techniques; Dose-Response Relationship, Drug; Gene Expression Regulation; Male; Mice; NF-kappa B; NFATC Transcription Factors; Osteoblasts; Osteoclasts; Osteoprotegerin; Phosphorylation; RANK Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transcription Factor RelA | 2012 |
Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.
Topics: Animals; Antioxidants; Berberine; Body Weight; Bone Density; Female; Femur; NF-kappa B; Osteoporosis; Osteoprotegerin; Oxidative Stress; RANK Ligand; Rats; Rats, Wistar; Signal Transduction | 2017 |